Internet Archive Scholar

58 KEYNOTE-826: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer

N Colombo, C Dubot, D Lorusso, V Caceres, K Hasegawa, R Shapira-Frommer, K Tewari, P Salman, E Hoyos Usta, E Yañez, M Gümüş, M Olivera Hurtado de Mendoza (+7 others)
2021 Late breaking abstracts   unpublished

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (77.4 kB)
https://web.archive.org/web/20220204213552/https://ijgc.bmj.com/content/ijgc/31/Suppl_3/A364.1.full.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL. The file type is application/pdf.

Introduction/Background* Identifying risk factors for lymph node metastases in early-stage cervical cancer may aid in tailoring treatment. Unfortunately, early-stage cervical cancer research is often hampered by small sample sizes.
doi:10.1136/ijgc-2021-esgo.641 fatcat:ueiigrb2gjeaxdonvdgainbmry
Citation

N Colombo, C Dubot, D Lorusso, V Caceres, K Hasegawa, R Shapira-Frommer, K Tewari, P Salman, E Hoyos Usta, E Yañez, M Gümüş, M Olivera Hurtado de Mendoza, V Samouëlian, V Castonguay, A Arkhipov, S Toker, K LI, S Keefe, B Monk. "58 KEYNOTE-826: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer." Late breaking abstracts (2021)